Journal article
Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017
S Ugurel, J Röhmel, PA Ascierto, KT Flaherty, JJ Grob, A Hauschild, J Larkin, GV Long, P Lorigan, GA McArthur, A Ribas, C Robert, D Schadendorf, C Garbe
European Journal of Cancer | ELSEVIER SCI LTD | Published : 2017
Abstract
The treatment of metastatic melanoma is still undergoing a process of major change. The two most important novel therapeutic strategies, selective kinase inhibitors and immune checkpoint blockers, both significantly prolong survival times of patients with advanced metastatic disease. Different agents, dose regimens and combinations have been tested against each other vigorously within these two groups. However, results from prospective head-to-head comparative studies of both strategies are still lacking. We performed an exploratory analysis of survival data from selected clinical trials representative for the new treatment strategies in advanced metastatic melanoma. Eighty-three Kaplan–Meie..
View full abstractGrants
Funding Acknowledgements
Selma Ugurel received relevant financial support from Bristol-Myers Squibb, medac, Merck Sharp & Dohme, Roche. Paolo A. Ascierto received relevant financial support as the advisory board/consultant for Bristol-Myers Squibb, Roche, Merck Sharp & Dohme, Array, Amgen, Novartis, Merck Serono, Pierre-Fabre; research fund from Bristol-Myers Squibb, Roche, Array. Keith T. Flaherty received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Jean Jacques Grob received relevant financial support from Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Roche. Axel Hauschild received relevant financial support (Amgen, Bristol-Myers Squibb, MerckSerono, Merck Sharp & Dohme, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche). James Larkin received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Georgina V. Long received relevant financial support from Amgen, Array, Bristol-Myers Squibb, Novartis, Merck, OncoSec, Pierre-Fabre, Roche. Paul Lorigan received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Grant A. McArthur received relevant financial support from Pfizer, Celgene. Antoni Ribas received relevant financial support from Bristol-Myers Squibb, Merck, Novartis, Roche. Caroline Robert received relevant financial support from Roche, GSK, Novartis, Amgen, BMS, Merck Sharp & Dohme. Dirk Schadendorf received relevant financial support from Roche, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme, Amgen, Boehringer Ingelheim, Leo. Claus Garbe received relevant financial support from Roche, GSK, Novartis, Bristol-Myers Squibb, Merck Sharp & Dohme. The remaining authors declare no conflict of interest.